32
total announcements
539524.BO · 15 min delayed
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd. is hosting a conference call to discuss its Q2 & H1 FY27 results on November 4, 2026. The call will be led by the company's management and will provide an opportunity for participants to ask questions.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced that its Board of Directors will consider a 2nd Interim Dividend for the Financial Year 2026-27 at its meeting on November 04, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/11/2026 to consider and approve the un-audited financial results for the quarter and half year ended on September 30, 2026, and to consider 2nd Interim Dividend, if any, for the Financial Year 2026-27.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has acquired the remaining 30% equity stake in Centrapath Labs Private Ltd, a subsidiary of its wholly-owned subsidiary PathLabs Unifiers Private Ltd, for INR 1608.352 per share.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has made a further investment in PathLabs Unifiers Private Limited, a wholly-owned subsidiary, by subscribing to its equity shares. The investment is intended to fund the acquisition of a 30% equity stake in CentraPath Labs Private Limited, a subsidiary of PathLabs Unifiers Private Limited.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has submitted a certificate confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has received an intimation of Income Tax appeal filed by the Income Tax Department before the Income Tax Appellate Tribunal, New Delhi, against the order allowing relief to the Company on disallowances of ESOP Expenses.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has completed the acquisition of a stake in SN Genelab Private Limited as per the terms and conditions of the Agreement.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, as per the agreement and prevailing provisions in Ghana. This makes Sunshine Healthcare Limited a step-down subsidiary of Dr. Lal PathLabs Ltd.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced the closure of its trading window from October 1, 2026, to November 6, 2026, ahead of its board meeting on November 4, 2026, to consider the un-audited financial results for the quarter and half-year ending September 30, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has scheduled a Board Meeting on November 04, 2026, to consider and approve the un-audited financial results for the quarter and half year ending September 30, 2026. The trading window will be closed from October 1, 2026, to November 06, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has acquired a 70% stake in SN Genelab Private Limited for up to INR 168 Crores, with the transaction expected to be completed by November 30, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has approved the acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 Crores, with the transaction expected to be completed by November 30, 2026.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has published a notice to Equity Shareholders regarding unclaimed Equity Shares (Interim Dividend FY 2019-20), due for transfer to Investor Education and Protection Fund (IEPF) pursuant to Section 124(6) of the Companies Act, 2013.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has completed the subscription of a 30% stake in Neuome Technologies Private Limited, making Neuome an associate of the company.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has incorporated a step-down subsidiary company, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, with its wholly-owned subsidiary Dr Lal PathLabs FZCO, Dubai, United Arab Emirates, subscribing to 70% of its share capital.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has informed the exchange about the allotment of 2,11,050 equity shares under its Employee Stock Option Plan 2022, increasing its paid-up equity share capital to INR 1,67,84,88,200 divided into 16,78,48,820 equity shares of INR 10/- each.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced its Q1 FY27 earnings conference call transcript, with a revenue of Rs. 798 crore, registering a year-on-year growth of 19.1%. The company has launched 116 new tests, including 4 first-in-India tests, and has expanded its advanced diagnostics capabilities.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has informed the exchange that Mr. Gurinder Singh Kalra has completed his tenure as an Independent Director of the Company on July 26, 2026, and ceases to be an Independent Director with effect from the same date.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd has announced the voting results of its 32nd Annual General Meeting (AGM), with the Scrutinizer's Report confirming the passing of all resolutions, including the adoption of audited financial statements for the financial year ended March 31, 2026.